GamaSTAN® immune globulin approved for hepatitis A and measles postexposure prophylaxis
by Press Release from Outbreak News Today on (#3Y9A2)
Grifols, a leading global producer of plasma-derived medicines, announced that the U.S. Food and Drug Administration (FDA) has approved a new formulation of its GamaSTAN(R) immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis. GamaSTAN(R) is now available to healthcare providers across the country. GamaSTAN(R) is the only immune globulin product on the U.S. market ["]
The post GamaSTAN(R) immune globulin approved for hepatitis A and measles postexposure prophylaxis appeared first on Outbreak News Today.